Kevin Damman

List of Publications by Year
in descending order

140 papers	17,730 citations	34076 52 h-index	15249 126 g-index
147 all docs	147 docs citations	147 times ranked	11099 citing authors

#	Article	IF	Citations
1	Changes in inferior vena cava area represent a more sensitive metric than changes in filling pressures during experimental manipulation of intravascular volume and tone. European Journal of Heart Failure, 2022, 24, 455-462.	2.9	16
2	The European Registry for Patients with Mechanical Circulatory Support of the European Association for Cardio-Thoracic Surgery: third report. European Journal of Cardio-thoracic Surgery, 2022, 62, .	0.6	18
3	Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. Heart, 2022, 108, 1342-1350.	1.2	81
4	Letter by Beldhuis et al Regarding Article, â€œPotential Role of Natriuretic Response to Furosemide Stress Test During Acute Heart Failureâ€. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121009006.	1.6	0
5	Natriuresisâ€guided therapy in acute heart failure: rationale and design of the <scp>Pragmatic Urinary Sodiumâ€based treatment algoritHm</scp> in <scp>Acute Heart Failure</scp> (<scp>PUSHâ€AHF</scp>) trial. European Journal of Heart Failure, 2022, 24, 385-392.	2.9	26
6	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	2.9	820
7	Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 228-239.	2.2	4
8	Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease. Circulation, 2022, 145, 693-712.	1.6	57
9	Renal effects of guidelineâ€directed medical therapies in heart failure: a consensus document from the Heart Failure <scp>Association of the European Society of Cardiology</scp>. European Journal of Heart Failure, 2022, 24, 603-619.	2.9	57
10	Urinary sodium: worth its salt?. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 701-702.	1.8	1
11	Conservative initial postoperative anticoagulation strategy after HeartMateÂ3Âleft ventricular assist device implantation. Netherlands Heart Journal, 2022, 30, 466-472.	0.3	1
12	Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. Circulation, 2022, 146, 438-449.	1.6	53
13	Clinical implications of low estimated protein intake in patients with heart failure. Journal of Cachexia, Sarcopenia and Muscle, 2022, , .	2.9	7
14	When two worlds collide: making sense of changes in renal function with lifeâ€saving heart failure therapies. European Journal of Heart Failure, 2022, 24, 1599-1600.	2.9	0
15	Acetazolamide in Decompensated Heart Failure with Volume Overload trial (<scp>ADVOR</scp>): baseline characteristics. European Journal of Heart Failure, 2022, 24, 1601-1610.	2.9	18
16	The European Registry for Patients with Mechanical Circulatory Support (EUROMACS): third Paediatric (Paedi-EUROMACS) report. European Journal of Cardio-thoracic Surgery, 2022, 62, .	0.6	6
17	Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. European Journal of Heart Failure, 2021, 23, 68-78.	2.9	79
18	The Effect of Decongestion on Intrarenal Venous Flow Patterns in Patients With Acute Heart Failure. Journal of Cardiac Failure, 2021, 27, 29-34.	0.7	29

#	Article	IF	Citations
19	Spironolactone in Patients With HeartÂFailure, Preserved Ejection Fraction, and Worsening Renal Function. Journal of the American College of Cardiology, 2021, 77, 1211-1221.	1.2	19
20	Dipeptidyl peptidase 3, a marker of the antagonist pathway of the reninâ€“angiotensinâ€“aldosterone system in patients with heart failure. European Journal of Heart Failure, 2021, 23, 947-953.	2.9	9
21	Prevention of heart failure events with sodiumâ€“glucose coâ€transporter 2 inhibitors across a spectrum of cardioâ€renalâ€metabolic risk. European Journal of Heart Failure, 2021, 23, 1002-1008.	2.9	25
22	The value of spot urinary creatinine as a marker of muscle wasting in patients with newâ€onset or worsening heart failure. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 555-567.	2.9	15
23	Propensity score-based analysis of long-term follow-up in patients supported with durable centrifugal left ventricular assist devices: the EUROMACS analysis. European Journal of Cardio-thoracic Surgery, 2021, 60, 579-587.	0.6	29
24	Donor Heart Preservation with Hydrogen Sulfide: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 2021, 22, 5737.	1.8	9
25	Effects of sodiumâ€“glucose coâ€transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure. European Journal of Heart Failure, 2021, 23, 1049-1052.	2.9	2
26	Postâ€transplant inotrope score is associated with clinical outcomes after adult heart transplantation. Clinical Transplantation, 2021, 35, e14347.	0.8	9
27	Risk and risk reduction in trials of heart failure with reduced ejection fraction: absolute or relative?. European Journal of Heart Failure, 2021, 23, 1437-1444.	2.9	9
28	Ganciclovir therapeutic drug monitoring in transplant recipients. Journal of Antimicrobial Chemotherapy, 2021, 76, 2356-2363.	1.3	23
29	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	1.0	5,558
30	Proenkephalin and the risk of newâ€onset heart failure: data from prevention of renal and vascular endâ€stage disease. Clinical Cardiology, 2021, , .	0.7	4
31	Abstract 11150: Albuminuria in Heart Failure is More Strongly Associated with Markers of Congestion Than Renal Dysfunction. Circulation, 2021, 144, .	1.6	0
32	The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. Clinical Research in Cardiology, 2020, 109, 331-338.	1.5	28
33	Randomized, doubleâ€blind, placeboâ€controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPAâ€RESPONSEâ€AHF). European Journal of Heart Failure, 2020, 22, 713-722.	2.9	260
34	Evaluation of kidney function throughout the heart failure trajectoryÂâ€“Âa position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 584-603.	2.9	213
35	Spironolactone: diuretic or diseaseâ€modifying drug in heart failure with preserved ejection fraction?. European Journal of Heart Failure, 2020, 22, 1611-1614.	2.9	2
36	Reduced Diuretic Dose in Patients Treated With Eplerenone. Circulation: Heart Failure, 2020, 13, e006597.	1.6	11

#	Article	IF	Citations
37	Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nature Reviews Cardiology, 2020, 17, 641-655.	6.1	143
38	Clinical importance of urinary sodium excretion in acute heart failure. European Journal of Heart Failure, 2020, 22, 1438-1447.	2.9	55
39	Urinary sodium evaluation: the missing target for diuretic treatment optimization in acute heart failure patients? Reply. European Journal of Heart Failure, 2020, 22, 1933-1934.	2.9	0
40	Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. Clinical Research in Cardiology, 2020, 109, 1048-1059.	1.5	20
41	A Patient with Progressive Renal Insufficiency in Chronic Heart Failure with Reduced Ejection Fraction. , 2020, , 75-87.		0
42	Down the road from challenges in acute heart failure trials. European Journal of Heart Failure, 2019, 21, 1423-1425.	2.9	4
43	Response to Cardiac Resynchronization Therapy Across Chronic Kidney Disease Stages. Journal of Cardiac Failure, 2019, 25, 803-811.	0.7	10
44	Trajectories of Changes in Renal Function in Patients with Acute Heart Failure. Journal of Cardiac Failure, 2019, 25, 866-874.	0.7	16
45	Dyssynchronopathy Can be a Manifestation of Heritable Cardiomyopathy. Circulation Genomic and Precision Medicine, 2019, 12, e002528.	1.6	0
46	Response to letters on â€œThe use of diuretics in heart failure with congestion â€“ a position statement from the Heart Failure Association of the European Society of Cardiologyâ€• European Journal of Heart Failure, 2019, 21, 949-950.	2.9	4
47	Urinary Sodium Profiling in Chronic HeartÂFailure to Detect Development of Acute Decompensated Heart Failure. JACC: Heart Failure, 2019, 7, 404-414.	1.9	42
48	Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure. Circulation: Heart Failure, 2019, 12, e005544.	1.6	23
49	Reply to letters on â€œThe use of diuretics in heart failure with congestion â€” a position statement from the Heart Failure Association of the European Society of Cardiologyâ€• European Journal of Heart Failure, 2019, 21, 949.	2.9	1
50	Impact of Renal Impairment on Beta-Blocker Efficacy in PatientsÂWithÂHeartÂFailure. Journal of the American College of Cardiology, 2019, 74, 2893-2904.	1.2	39
51	1538. Who Will Benefit From Therapeutic Drug Monitoring of Ganciclovir?. Open Forum Infectious Diseases, 2019, 6, S560-S561.	0.4	0
52	Very Early Diuretic Response After Admission for Acute Heart Failure. Journal of Cardiac Failure, 2019, 25, 12-19.	0.7	18
53	The use of diuretics in heart failure with congestion â€” a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 137-155.	2.9	605
54	Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic KidneyÂDisease. JACC: Heart Failure, 2019, 7, 25-32.	1.9	51

#	Article	IF	Citations
55	Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC: Heart Failure, 2018, 6, 489-498.	1.9	272
56	You do something to me, something deep inside. European Journal of Heart Failure, 2018, 20, 801-802.	2.9	0
57	Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. International Journal of Cardiology, 2018, 253, 84-90.	0.8	55
58	Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. International Journal of Cardiology, 2018, 258, 185-191.	0.8	157
59	Diuretics in cardiorenal syndrome: whatâ€™s new?. Intensive Care Medicine, 2018, 44, 359-362.	3.9	4
60	Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.9	73
61	Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. International Journal of Cardiology, 2018, 271, 132-139.	0.8	140
62	Waistâ€toâ€hip ratio and mortality in heart failure. European Journal of Heart Failure, 2018, 20, 1269-1277.	2.9	85
63	Successful emergent repair of a subacute left ventricular free wall rupture after acute inferoposterolateral myocardial infarction. Journal of Cardiothoracic Surgery, 2018, 13, 82.	0.4	3
64	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. European Heart Journal, 2018, 39, 3867-3875.	1.0	47
65	Rationale and design of TransplantLines: a prospective cohort study and biobank of solid organ transplant recipients. BMJ Open, 2018, 8, e024502.	0.8	71
66	Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure. European Journal of Heart Failure, 2017, 19, 1014-1022.	2.9	80
67	Reninâ€“Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction. Circulation: Heart Failure, 2017, 10, .	1.6	89
68	The importance of myocardial contractile reserve in predicting response to cardiac resynchronization therapy. European Journal of Heart Failure, 2017, 19, 862-869.	2.9	27
69	Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. Heart, 2017, 103, 407-413.	1.2	74
70	Heart failure with preserved ejection fraction: a nephrologist-directed primer. Heart Failure Reviews, 2017, 22, 765-773.	1.7	14
71	Time-to-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure. Journal of the American College of Cardiology, 2017, 69, 3042-3051.	1.2	235
72	Heart rate and outcome in heart failure with reduced ejection fraction: Differences between atrial fibrillation and sinus rhythmâ€”A <scp>CIBIS II</scp> analysis. Clinical Cardiology, 2017, 40, 740-745.	0.7	16

#	Article	IF	Citations
73	Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction. Clinical Research in Cardiology, 2017, 106, 802-812.	1.5	30
74	Clinical and prognostic value of spot urinary creatinine in chronic heart failureâ€"An analysis from GISSI-HF. American Heart Journal, 2017, 188, 189-195.	1.2	10
75	Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements. European Journal of Heart Failure, 2017, 19, 1651-1660.	2.9	89
76	Clinical and Hemodynamic Correlates and Prognostic Value of VE/VCO 2 Slope in Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Hypertension. Journal of Cardiac Failure, 2017, 23, 777-782.	0.7	34
77	The Fastest Way to the Failing Heart Is Through the Kidneys. JACC: Heart Failure, 2017, 5, 682-683.	1.9	1
78	Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. Journal of Cardiac Failure, 2017, 23, 231-239.	0.7	30
79	Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and healthâ€related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. European Journal of Heart Failure, 2017, 19, 116-125.	2.9	50
80	Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.7	39
81	Progression of Renal Impairment and Chronic Kidney Disease in Chronic Heart Failure: An Analysis From GISSI-HF. Journal of Cardiac Failure, 2017, 23, 2-9.	0.7	26
82	Plasma Neutrophil Gelatinase-Associated Lipocalin and Predicting Clinically Relevant Worsening Renal Function in Acute Heart Failure. International Journal of Molecular Sciences, 2017, 18, 1470.	1.8	17
83	Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2016, 18, 328-336.	2.9	88
84	Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. European Journal of Heart Failure, 2016, 18, 588-598.	2.9	242
85	Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	80
86	Plasma kidney injury moleculeâ€1 in heart failure: renal mechanisms and clinical outcome. European Journal of Heart Failure, 2016, 18, 641-649.	2.9	32
87	Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the ‹scp›CHARM‹/scp›â€study programme. European Journal of Heart Failure, 2016, 18, 1508-1517.	2.9	54
88	Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	35
89	Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure. European Heart Journal, 2016, 37, 2577-2585.	1.0	82
90	A combined clinical and biomarker approach to predict diuretic response in acute heart failure. Clinical Research in Cardiology, 2016, 105, 145-153.	1.5	32

#	Article	IF	Citations
91	Long-term changes in renal function and perfusion in heart failure patients with reduced ejection fraction. Clinical Research in Cardiology, 2016, 105, 10-16.	1.5	17
92	Neutrophil Gelatinase Associated Lipocalin (NGAL) as a Biomarker for Cardiovascular Disease. , 2016, , 407-423.		0
93	Recommendations on preâ€hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. European Journal of Heart Failure, 2015, 17, 544-558.	2.9	315
94	Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine â€“ short version. European Heart Journal, 2015, 36, 1958-1966.	1.0	105
95	Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Heart Journal, 2015, 169, 693-701.e3.	1.2	16
96	Diuretic response in acute heart failureâ€"pathophysiology, evaluation, and therapy. Nature Reviews Cardiology, 2015, 12, 184-192.	6.1	198
97	The kidney in heart failure: an update. European Heart Journal, 2015, 36, 1437-1444.	1.0	384
98	Diuretic response in acute heart failureâ€"an analysis from ASCEND-HF. American Heart Journal, 2015, 170, 313-321.e4.	1.2	110
99	Effect of Metformin on Renal Function After Primary Percutaneous Coronary Intervention in Patients Without Diabetes Presenting with ST-elevation Myocardial Infarction: Data from the GIPS-III Trial. Cardiovascular Drugs and Therapy, 2015, 29, 451-459.	1.3	18
100	Neutrophil Gelatinase Associated Lipocalin (NGAL) as a Biomarker for Cardiovascular Disease. , 2015, , 1-17.		0
101	Creatinine excretion rate, a marker of muscle mass, is related to clinical outcome in patients with chronic systolic heart failure. Clinical Research in Cardiology, 2014, 103, 976-983.	1.5	34
102	Renal Handling of Galectinâ€3 in the General Population, Chronic Heart Failure, and Hemodialysis. Journal of the American Heart Association, 2014, 3, e000962.	1.6	46
103	The Chronic Kidney Disease Epidemiology Collaboration equation outperforms the Modification of Diet in Renal Disease equation for estimating glomerular filtration rate in chronic systolic heart failure. European Journal of Heart Failure, 2014, 16, 86-94.	2.9	102
104	A Combined-Biomarker Approach to Clinical Phenotyping Renal Dysfunction in Heart Failure. Journal of Cardiac Failure, 2014, 20, 912-919.	0.7	46
105	Why and when should we worry about worsening renal function?. European Journal of Heart Failure, 2014, 16, 4-5.	2.9	7
106	Prognostic Value of Plasma Neutrophil Gelatinaseâ€"Associated Lipocalin for Mortality in Patients With Heart Failure. Circulation: Heart Failure, 2014, 7, 35-42.	1.6	92
107	Pathophysiology of the Cardiorenal Syndromes: Executive Summary from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). Blood Purification, 2014, 37, 2-13.	0.9	7
108	Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency. Journal of the American College of Cardiology, 2014, 63, 853-871.	1.2	102

#	Article	IF	Citations
109	Co-morbidities in heart failure. Heart Failure Reviews, 2014, 19, 163-172.	1.7	48
110	Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. European Heart Journal, 2014, 35, 455-469.	1.0	747
111	Diuretic response in acute heart failure: clinical characteristics and prognostic significance. European Heart Journal, 2014, 35, 1284-1293.	1.0	276
112	Coâ€morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. European Journal of Heart Failure, 2014, 16, 103-111.	2.9	355
113	Terminology and definition of changes renal function in heart failure. European Heart Journal, 2014, 35, 3413-3416.	1.0	108
114	Periprocedural Complications andÂLong-Term Outcome AfterÂAlcoholÂSeptalÂAblation VersusÂSurgical MyectomyÂin Hypertrophic Obstructive Cardiomyopathy. JACC: Cardiovascular Interventions, 2014, 7, 1227-1234.	1.1	64
115	Worsening Renal Function and Outcome inÂHeart Failure Patients With Preserved Ejection Fraction and the Impact of Angiotensin Receptor Blocker Treatment. Journal of the American College of Cardiology, 2014, 64, 1106-1113.	1.2	67
116	Clinical Risk Stratification Optimizes Value of Biomarkers to Predict New-Onset Heart Failure in a Community-Based Cohort. Circulation: Heart Failure, 2014, 7, 723-731.	1.6	74
117	Are Reninâ€“Angiotensinâ€“Aldosterone System Inhibitors Lifesaving in Chronic Kidney Disease?. Journal of the American College of Cardiology, 2014, 63, 659-660.	1.2	5
118	Liver Function, In-Hospital, and Post-Discharge Clinical Outcome in Patients With Acute Heart Failureâ€”Results From the Relaxin for the Treatment of Patients With Acute Heart Failure Study. Journal of Cardiac Failure, 2014, 20, 407-413.	0.7	38
119	Tubular Damage and Worsening Renal Function in Chronic Heart Failure. JACC: Heart Failure, 2013, 1, 417-424.	1.9	87
120	The WAP Four-Disulfide Core Domain Protein HE4: A Novel Biomarker for Heart Failure. JACC: Heart Failure, 2013, 1, 164-169.	1.9	40
121	Beta-Blockers and Outcome in Heart Failure and Atrial Fibrillation. JACC: Heart Failure, 2013, 1, 21-28.	1.9	123
122	Pathophysiology of the Cardiorenal Syndromes: Executive Summary from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). Contributions To Nephrology, 2013, 182, 82-98.	1.1	135
123	Venous congestion and renal function in heart failure â€¦ it's complicated. European Journal of Heart Failure, 2013, 15, 599-601.	2.9	32
124	Neutrophil gelatinase-associated lipocalin and worsening renal function in acute heart failure. Journal of Cardiovascular Medicine, 2013, 14, 635-636.	0.6	0
125	Use of cystatin C levels in estimating renal function and prognosis in patients with chronic systolic heart failure. Heart, 2012, 98, 319-324.	1.2	49
126	Urinary Proteins in Heart Failure. Progress in Cardiovascular Diseases, 2012, 55, 44-55.	1.6	31

#	Article	IF	Citations
127	Current and novel renal biomarkers in heart failure. Heart Failure Reviews, 2012, 17, 241-250.	1.7	38
128	Volume Status and Diuretic Therapy in Systolic Heart Failure and the Detection of Early Abnormalities in Renal and Tubular Function. Journal of the American College of Cardiology, 2011, 57, 2233-2241.	1.2	121
129	The Cardiorenal Syndrome in Heart Failure. Progress in Cardiovascular Diseases, 2011, 54, 144-153.	1.6	83
130	Clinical outcome of renal tubular damage in chronic heart failureâ€. European Heart Journal, 2011, 32, 2705-2712.	1.0	174
131	Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart, 2010, 96, 1297-1302.	1.2	179
132	Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. European Journal of Heart Failure, 2010, 12, 974-982.	2.9	140
133	PATHOPHYSIOLOGICAL MECHANISMS CONTRIBUTING TO RENAL DYSFUNCTION IN CHRONIC HEART FAILURE. Journal of Renal Care, 2010, 36, 18-26.	0.6	17
134	Both inâ€•and outâ€•hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH). European Journal of Heart Failure, 2009, 11, 847-854.	2.9	157
135	Response to Letter Regarding Article, â€œImpact of Pretreatment With Clopidogrel on Initial Patency and Outcome in Patients Treated With Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: A Systematic Review. Circulation, 2009, 120, .	1.6	1
136	Differential associations between renal function and â€œmodifiableâ€•risk factors in patients with chronic heart failure. Clinical Research in Cardiology, 2009, 98, 121-129.	1.5	101
137	Increased Central Venous Pressure Is Associated With Impaired Renal Function and Mortality in a Broad Spectrum of Patients With Cardiovascular Disease. Journal of the American College of Cardiology, 2009, 53, 582-588.	1.2	796
138	Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. European Journal of Heart Failure, 2008, 10, 997-1000.	2.9	181
139	Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. European Journal of Heart Failure, 2007, 9, 872-878.	2.9	393
140	Worsening Renal Function and Prognosis in Heart Failure: Systematic Review and Meta-Analysis. Journal of Cardiac Failure, 2007, 13, 599-608.	0.7	527